CAR T-cell Therapy | Specialty

Initial Steps for Treatment of DLBCL

May 25th 2018

Dr. Perl on Remaining Challenges with CAR T-Cell Therapy

May 23rd 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses remaining challenges with chimeric antigen receptor (CAR) T-cell therapy.

CAR T-Cell Therapy, Checkpoint Inhibitors Making Waves Across Hematologic Malignancies

May 18th 2018

Anas Younes, MD, discusses the current and future state of CAR T-cell therapies and immune checkpoint inhibitors in the landscape of hematologic malignancies.

CAR T-Cell Payment Codes Don't Address True Cost

May 17th 2018

CMS's initial payment codes for CAR T-cell therapies are opposed by the medical community on the basis that they would be cumbersome to implement and wouldn't reflect the full amount of care delivered to each patient.

Dr. Brentjens Discusses Targets for CAR T-Cell Therapy

May 8th 2018

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy.

Tisagenlecleucel Safety, Efficacy Promising in Pediatric Down Syndrome and ALL

May 4th 2018

A first-time study of chimeric antigen receptor T-cell therapy in youths with Down syndrome-associated relapsed/refractory (r/r) acute lymphoblastic leukemia produced high remission rates and toxicity results that were similar to those observed in patients with r/r ALL.

Selective T-Cell Depletion Improves Engraftment, Reduces GVHD in Pediatric/AYA Leukemia

May 4th 2018

Eliminating T cells carrying alpha and beta chains of the T-cell receptor reduced the risk for graft-versus-host-disease while producing "excellent" engraftment kinetics for young patients with acute leukemia who underwent hematopoietic stem cell transplant.

Memory-Related Genes May Overcome Resistance to CAR T-Cell Therapy in CLL

May 3rd 2018

Results from a recent study may show why some patients with chronic lymphocytic leukemia are resistant to tisagenlecleucel, while potentially offering a pathway to enhance patient response.

Dr. Flinn on FDA Approval of Tisagenlecleucel in DLBCL

May 2nd 2018

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.

FDA Approves Tisagenlecleucel for Large B-Cell Lymphoma

May 2nd 2018

The FDA has approved tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.

Expert Covers Burgeoning Role of CAR T-Cell Therapy in Myeloma

April 26th 2018

Maung Myo Htut, MD, discusses the use of CAR T-cell therapy in multiple myeloma and the potential infusion of immunotherapy into treatment.

CAR T-Cell Therapy Starts to Enter MCL Space

April 23rd 2018

Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.

FT819 Derives Renewable, Reproducible Process of CAR T-Cell Therapy

April 16th 2018

An off-the-shelf, dual-targeted chimeric antigen receptor T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies.

Dr. Younes Discusses the Future of CAR T-Cell Therapy

April 10th 2018

Anas Younes, MD, chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

Dr. Park on CD19-Directed CAR T-Cell Therapy in Patients With ALL

April 6th 2018

Jae Park, MD, hematologist oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in adult patients with acute lymphoblastic leukemia (ALL).

Novel Agents, CAR T Cells Reinvigorate ALL Landscape

April 5th 2018

Jae H. Park, MD, discusses the impact of agents such as blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel on the treatment of acute lymphoblastic leukemia.

Dr. Brentjens on Managing Patients After CAR T-Cell Therapy

April 4th 2018

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses managing patients after treatment with chimeric antigen receptor (CAR) T-cell therapy.

Dr. Perl on Potential CAR T-Cell Therapies in Hematologic Malignancies

March 28th 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses potential chimeric antigen receptor (CAR) T-cells in hematologic malignancies.

Dr. Winter Discusses the ZUMA-7 Trial in DLBCL

March 27th 2018

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial (NCT03391466) in diffuse large B-cell lymphoma (DLBCL).

Brentjens Highlights BCMA, Next Steps With CAR T-Cell Therapy

March 22nd 2018

Renier J. Brentjens, MD, PhD, discusses the emergence of BCMA as a target for CAR T-cell therapy and other next steps for the field.